Among Asians diagnosed with lung adenocarcinoma, approximately 50–60% of patients harbor an EGFR mutation [3,4] and could benefit from EGFR-tyrosine kinase inhibitor (TKI) therapy [5,6]. The gene discussed is EGFR; the disease is lung adenocarcinoma.